Positives

• A claims-based analysis found patients on spironolactone had a 72% lower risk of severe COVID outcomes, supporting a possible aldosterone-axis benefit, per a PubMed retrospective cohort study.
  
  
• Patients on low-dose spironolactone in a hospitalized COVID trial saw reduced D-dimer and aldosterone levels with good tolerability, per a BMC Infectious Diseases trial report.
  
  

Negatives

• Female patients commonly report initial telogen effluvium hair shedding and breast tenderness during the first few months of treatment, with this pattern reflected in Drugs.com patient reviews.
  
  
• Some patients describe orthostatic dizziness and frequent urination that worsens existing POTS-like symptoms, per a Drugs.com Q&A discussion.
  
  

Hurdles & Side Effects

• Patients require periodic potassium and creatinine monitoring, particularly when combining with ACE inhibitors or ARBs already used for hypertension, per Mayo Clinic's spironolactone monograph.
  
  
• No specific FDA indication exists for Long COVID, so patients must find a clinician willing to prescribe off-label for cardiovascular or hormonal post-COVID symptoms, per a Future Virology systematic review.